Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation …
H Tada, T Mitsudomi, T Misumi, K Sugio… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
[HTML][HTML] Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: a systematic literature review
M Khasraw, P Yalamanchili, A Santhanagopal… - Advances in …, 2024 - Springer
Method A Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)-
compliant SLR was conducted to identify studies in patients with BrMs in NSCLC. Searches …
compliant SLR was conducted to identify studies in patients with BrMs in NSCLC. Searches …
[HTML][HTML] Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an …
DF Chamorro, AF Cardona, J Rodríguez… - Targeted Oncology, 2023 - Springer
Background Epidermal growth factor receptor (EGFR) mutations (EGFR m) represent one of
the most common genomic alterations identified among patients with non-small cell lung …
the most common genomic alterations identified among patients with non-small cell lung …
[HTML][HTML] Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer …
HA Jung, MH Hong, HW Lee, KH Lee… - … lung cancer Research, 2022 - ncbi.nlm.nih.gov
Background Irrespective of the first-line epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key …
kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key …
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
[HTML][HTML] Effectiveness and tolerability of first-line afatinib for advanced EGFR-mutant non-small cell lung cancer in Vietnam
TH Vu, HTT Nguyen, LK Dao, CK Duong… - Asian Pacific Journal …, 2021 - ncbi.nlm.nih.gov
Background: We aimed to evaluate the effectiveness and tolerability of Afatinib as first-line
treatment of advanced epidermal growth factor receptor (EGFR) mutant non small cell lung …
treatment of advanced epidermal growth factor receptor (EGFR) mutant non small cell lung …
[HTML][HTML] The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung …
HA Jung, S Park, SH Lee, JS Ahn… - Cancer Research and …, 2023 - ncbi.nlm.nih.gov
Purpose Brain metastasis is common in patients with epidermal growth factor receptor
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
[HTML][HTML] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
L Kang, J Mai, W Liang, Q Zou, C Huang, Y Lin… - Frontiers in …, 2023 - frontiersin.org
Background: Afatinib is a potent, irreversible second-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non …
receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non …
[HTML][HTML] Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
JS Ju, ACC Huang, PH Tung, CH Huang, TH Chiu… - Scientific Reports, 2023 - nature.com
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …
[HTML][HTML] The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report
J Zang, H Horinouchi, J Hanaoka, K Funai… - Journal of Thoracic …, 2021 - ncbi.nlm.nih.gov
Studies have revealed that the epidermal growth factor receptor (EGFR) mutation is one of
the driving mutations in non-small cell lung cancer (NSCLC)(1, 2). Thus, EGFR tyrosine …
the driving mutations in non-small cell lung cancer (NSCLC)(1, 2). Thus, EGFR tyrosine …